 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--- NBTX ASCO--Regulatory News: Please replace the release dated May 19, 2021 with the following corrected version due to multiple revisions. NANOBIOTIX ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND IMMUNOTHERAPY FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 AT 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY Updated results from phase I dose expansion in head and neck cancer showed durable signs of efficacy at a me 